Contribute Try STAT+ Today

As pharmaceutical companies have reported their earnings over the past two weeks, it’s been like staring at a foreboding sky, guessing: Will it merely drizzle? Or will there be a storm, and a flood?

The reason? Worries about drug prices. What else. As Pfizer’s new chief executive, Albert Bourla, said during a question-and-answer session with analysts: It’s “very clear that pricing is not going to be a growth driver for us now and, I think, in the future. It’s very clear.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Matthew not matter how the sentence is framed, storm clouds are here to stay. No Easing!

    Only avenue for the pharma companies that do not have/produce orphan drugs is to raise prices of the existing drugs.

    Why? Answer is simple. They do not have many new drugs that are for masses and affordable and can offset the revenue gain that companies get from price increases of existing drugs.

    Marginally better drugs that are high priced are white elephants that no one wants to use.

    Basically what all that means. Pharma’s existing business model that is OOOOLD is broken and beyond repair. Need new model that will also serve ~80% of the global population.

  • Is this sentence correct: “This means that there is a 9 percentage point difference between what a consumer would pay at the drug counter and what pharmaceutical companies received.”. There was, on average, an additional 9% differential due to the price changes, but it doesn’t mean there’s only a 9% difference. This sort of thing could happen in multiple quarters, and there was likely an initial price differential.

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy